Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00051675 | Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas | PHASE1 | COMPLETED | 30 | — | — | Jul 1, 2002 | Sep 1, 2003 | Jun 24, 2005 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| ING-1(heMAb) | DRUG | - |
Inclusion Criteria 1. Subject has adenocarcinomas of the ovary, breast, lung, prostate, colon or rectum. 2. Subject has an advanced metastatic adenocarcinoma that is either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist. 3. Subject has ...